Valor202020212022202320242025TTMFluxo de caixa de investimento—————-6 000—Fluxo de caixa de financiamento—————14.12 M—Fluxo de caixa livre—————-20.12 M—
Oncolytics Biotech Inc. - Common Stock
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.